abs15.txt	in	2017		due	to	a	fluid	shortage	secondary	to	hurricane	maria's	devastation	ofpuerto	rico		hospitals	and	health-systems	began	to	substitute	rolapitant	forfosaprepitant	as	part	of	chemotherapy-induced	nausea	and	vomiting	prevention	andtreatment	strategies		however		despite	advantageous	pharmacologic	and	formulation(e	g		long	half-life		quicker	time	to	onset		and	lack	of	first-pass	hepaticmetabolism)	profiles		there	seems	to	be	significant	risk	of	infusion-relatedhypersensitivity	reactions	associated	with	the	administration	of	intravenousrolapitant		in	january	2018		the	u	s		fda	issued	a	health	care	provider	letterstating	that	anaphylaxis		anaphylactic	shock		and	other	serious	hypersensitivityreactions	have	been	reported	in	the	postmarketing	setting		importantly		thesereactions	were	observed	at	a	higher	rate	than	initially	reported	in	the	phase	1bioequivalence	study	that	led	to	fda	approval	of	intravenous	rolapitant	(2	8%)	with	many	resulting	in	hospitalizations		at	our	institution		rolapitant-inducedinfusion-related	reactions	also	occurred	in	more	patients	than	expected	(8	7%)	described	herein	are	six	cases	of	infusion-related	hypersensitivity	reactionswith	intravenous	rolapitant	at	the	north	carolina	cancer	hospital		due	to	thequick	onset	of	the	infusion-related	hypersensitivity	reactions	with	intravenousrolapitant		interpatient	differences	in	pharmacokinetics	or	pharmacodynamics	areunlikely	to	be	the	cause		an	objective	assessment	utilizing	the	naranjo	causalityscale	rates	these	infusion-related	hypersensitivity	reactions	as	definite	adversedrug	reactions	
